Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant

ClinicalTrials.gov ID: NCT00104065

Public ClinicalTrials.gov record NCT00104065. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 5:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of CG53135-05 Administered Intravenously as a Single Dose for the Prevention of Oral Mucositis in Patients Receiving Autologous Hematopoietic Stem Cell Transplant

Study identification

NCT ID: NCT00104065
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: CuraGen Corporation; Industry
Enrollment: Not listed

Conditions and interventions

Conditions

Stomatitis

Interventions

CG53135-05, velafermin Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 31, 2004
Primary completion: Nov 30, 2005
Completion: Nov 30, 2005
Last update posted: Mar 14, 2016

2005

United States locations

U.S. sites: 9
U.S. states: 9
U.S. cities: 9

Facility	City	State	ZIP	Site status
Research Facility	La Jolla	California	92037	—
Research Facility	Denver	Colorado	80218	—
Research Facility	Miami	Florida	33136	—
Research Facility	Chicago	Illinois	60611	—
Research Facility	Worcester	Massachusetts	01655	—
Research Facility	New York	New York	10021	—
Research Facility	Winston-Salem	North Carolina	27157	—
Research Facility	Cleveland	Ohio	44195	—
Research Facility	Portland	Oregon	97239	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00104065, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 14, 2016 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00104065 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →